The "lothar" Study: Evaluation Of Efficacy And Tolerability Of The Fixed Combination Of Amlodipine And Losartan In The Treatment Of Essential Hypertension

OBJECTIVE: The LOTHAR study evaluated medium and long term (one year) efficacy, tolerability and metabolic effects of the fixed combination of amlodipine and losartan compared to amlodipine or losartan alone. METHODS: Brazilian multicenter, randomized, double-blind and comparative trial performed with 198 patients in stage 1 and 2 essential hypertension. RESULTS: The fixed combination has a high antihypertensive efficacy that is sustained in the long term with very low percentage of loss of blood pressure control. This percentage is incidentally lower than that of the two monotherapy comparative regimens. In the long term, more than 60% of the patients treated with the fixed combination remained with DBP ≤ 85 mmHg, and the antihypertensive effect, when assessed by ABPM persisted for 24 hours with a trough-to-peak ratio of 76.7%. The frequency of adverse events was quite low in this group, and the long-term incidence of leg edema was approximately four-fold lower than that observed with amlodipine alone. The fixed combination did not change glucose and lipid metabolism in the medium or in the long term. CONCLUSION: Based on these results, we can say that the combination of amlodipine and losartan - the first fixed combination of a calcium channel blocker and an angiotensin II receptor blocker available in the pharmaceutical market, is an excellent option for the treatment of a wide range of hypertensive patients.8613951Sykowsky, P.A., D'Agostino, R.B., Belanger, A.J., Kannel, W.B., Secular Trends in Long Term Sustained Hypertension, Long Term Treatment and Cardiovascular Morbidity. The Framingham Heart Study 1950-1990 (1996) Circulation, 93, pp. 697-703MacMahon, S., Peto, R., Cutler, J., Blood Pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: Prospective observational studies corrected for regression dilution bias (1990) Lancet, 335, pp. 765-777IV Diretrizes Brasileiras de Hipertensão Arterial - Sociedade Brasileira de Hipertensão;Sociedade Brasileira de Cardiologia e Sociedade Brasileira de Nefrologia (2003) Hipertensão, 5 (4), pp. 126-163Chobaniam, A.V., Bakris, G.L., Black, H.R., Seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure- JNC 7 (2003) Hypertension, 42, pp. 1206-12522003 European Society of Hypertension - European Society of Cardiology guidelines for management of arterial hypertension (2003) J Hypertens, 21, pp. 1011-1053Hansson, L., Zanchetti, A., Carruthers, S.G., Dahlof, B., Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial (1998) Lancet, 351, pp. 1755-1762Opie, L.H., Frishman, W.H., Thadani, U., Calcium channel antagonists(Calcium Entry Blockers) (1995) Drugs for the Heart. 4th Ed., pp. 50-82. , Opie LH. (ed) Philadelphia: WB Saunders CoWebster, J., Robb, O.J., Jeffers, T.A., Scott, A.K., Petrie, J.C., Towler, H.M., Once daily amlodipine in the treatment of mild to moderate hypertension (1987) Br J Clin Pharmacol, 24 (6), pp. 713-719Dahlof, B., Devereux, R., Kjeldsen, S., Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol (2002) Lancet, 359, pp. 995-1003Lindholm, L.H., Ibsen, H., Dahlof, B., Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol (2002) Lancet, 359, pp. 1004-1010See, S., Angiotensin II receptor blockers for the treatment of hypertension (2001) Expert Opin Pharmacotherapy, 2 (11), pp. 1795-1804Zanetti-Elshater, F., Pingitore, R., Beretta-Piccoli, C., Calcium antagonists for treatment of diabetes-associated hypertension: Metabolic and renal effects of amlodipine (1994) Am J Hypertens, 7, pp. 36-45Verdecchia, P., Reboldi, G., Angeli, F., Adverse Prognostic Significance in New Diabetes in treated hypertensive subjects (2004) Hypertension, 43, pp. 963-969Dunder, K., Bind, L., Zethelius, B., Increase in blood glucose concentration during antihypertensive treatment as predictor of myocardial infarction: A population-based cohort study (2003) BMJ, 326, pp. 681-685Law, M.R., Wald, N.J., Morris, J.K., Jordan, R.E., Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomized trials (2003) Brit Med J, 326, pp. 1427-1434Van Hamesvelt, H.W., Kloke, H.J., De Jong, D.J., Koene, R.A., Huysmans, F.T., Oedema formation with the vasodilators nifedipina and dyazoxide: Direct local effect or sodium retention (1996) J Hypertens, 14 (8), pp. 1041-1045Opie, L.H., Choosing the correct drug for the individual hypertensive patient (1992) Drugs, 44, pp. 147-155Prisant, L.M., Weir, M.R., Papademetriou, V., Low-dose drug combination therapy: An alternative first-line approach to hypertension treatment (1995) Am Heart J, 130 (2), pp. 359-366Basile, J.N., Combination Agents as a means of improving adherence and other aspects of the sixth Joint National Committee Report (2000) South Med J, 93 (5), pp. 534-536Franco, R.J., Goldflus, S., McQuity, M., Oigman, W., Efficacy and tolerability of the combination of valsartan/ hydrochlorothiazide compared with amlodipine in mild-to-moderately hypertensive Brazilian population (2003) Blood Press, 2 (SUPPL.), pp. 41-47Ruilope, L.M., Malacco, E., Khder, Y., Kandra, A., Bonner, G., Heintz, D., Efficacy and tolerability of combination therapy with valsartan plus hydroclorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: The VAST study (2005) Clin Ther, 27 (5), pp. 578-587Mancia, G., Grassi, G., Systolic and diastolic blood pressure control in antihypertensive drug trials (2002) J Hypertens, 20, pp. 1461-1514Claxton, A.J., Cramer, J., Pierce, C., A systematic review of the association between dose regimens and medication compliance (2001) Clin Ther, 23 (8), pp. 1296-1310Bloom, B.S., Continuation of initial antihypertensive medication after 1 year of therapy (1998) Clin Ther, 20, pp. 671-681Varrone, J., A study of the efficacy and safety of amlodipine for the treatment o hypertension in general practice (1991) Postgrad Med J, 67 (5 SUPPL.), pp. S28-S31Weber, M.A., Smith, D.H., Neutel, J.M., Graettinger, W.F., Cardiovascular and metabolic characteristics of hypertension (1991) Am J Med, 91 (1 A), pp. 4S-10SReaven, G.M., Lithel, H., Landsberg, G.L., Mechanism of disease hypertension and associated metabolic abnormalities. The role of insulin resistance and the sympatho-adrenal system (1996) N Engl J Med, 334, pp. 374-382Hulthe, J., Bokemark, L., Wikstrand, J., The metabolic syndrome, LDL particle size and atherosclerosis: The Atherosclerosis and Insulin Resistance (AIR) Study (2000) Artherioscler Thromb Vasc Biol, 20 (9), pp. 2140-2147Kohlmann Jr., O., Resistência à insulina e hipertensão arterial: Relevância clínica (1998) Hipertensão, 1 (2), pp. 50-54Donahoo, W.T., Kosmiski, L.A., Eckel, R.H., Drugs causing dyslipoproteinemia (1998) Endocrinol Met Clin North Am, 27 (3), pp. 677-69